Sentences with phrase «by immune checkpoint inhibitors»

Detection of immune cell checkpoint and functional markers in the lung TME: The field of cancer immunotherapy continues to expand rapidly over recent years, with promising clinical results by immune checkpoint inhibitors and other therapeutic approaches.

The cancer cells» defense strategy can be overcome by immune checkpoint inhibitor agents, including anti-PD-1 / PD - L1 antibodies, several kinds of which have received fast - track approval from the U.S. Food and Drug Administration (FDA).

Not exact matches

The class of medications that he conceived, known as immune checkpoint inhibitors, works counterintuitively: By turning off one of the immune system's built - in safeguards, the inhibitors allow T cells — the system's foot soldiers — to attack tumors more effectively.

Known as a checkpoint inhibitor, tremelimumab is an investigational monoclonal antibody that «cuts the brakes» of the immune system by targeting cytotoxic T - lymphocyte antigen 4 (CTLA - 4), a protein that can switch off a patient's immune response.

Once again, researchers at Penn's Abramson Cancer Center have extended the reach of the immune system in the fight against metastatic melanoma, this time by combining the checkpoint inhibitor tremelimumab with an anti-CD40 monoclonal antibody drug.

Researchers led by Van Allen and Choueiri sought an explanation for why some patients with a form of metastatic kidney cancer called clear cell renal cell cancer (ccRCC) gain clinical benefit — sometimes durable — from treatment with immune checkpoint inhibitors that block the PD - 1 checkpoint, while other patients don't.

The drugs, ipilimumab (Yervoy ®) and nivolumab (Opdivo ®), made by Bristol - Myers Squibb (BMS), are two immune checkpoint inhibitors that «release the brakes» on the immune system, allowing it to mount a stronger and more effective attack against cancer.

The data presented provide new insights on the potential mechanism by which Seres» microbiome therapies could improve the outcomes of cancer patients treated with immune checkpoint inhibitors.

T - cells (red, yellow, and blue) attack a tumour in a mouse model of breast cancer following treatment with radiation and a PD - L1 immune checkpoint inhibitor, as seen by transparent tumour tomography.

The first generation of immunotherapies, including immune checkpoint inhibitors and cancer vaccines, have been limited by the proportion of patients who benefit, and by the depth and duration of response in those that do.

In an effort to further exploit the potential of Pexa - Vec to activate the immune system to fight cancer, as seen in McDonald's preclinical data, SillaJen recently announced a new clinical trial in collaboration with New York - based Regeneron Inc. to test Pexa - Vec and REGN2810, a PD - 1 checkpoint inhibitor, in combination against renal cell carcinoma, and recently signed a sponsored research agreement with UCSF to enable joint support of parallel preclinical experiments by McDonald's team.

By blocking these inhibitory molecules or, alternatively, activating stimulatory molecules, checkpoint inhibitors are designed to unleash or enhance pre-existing anti-cancer immune responses.

Led by Leena Gandhi, MD, PhD, associate professor of medicine and director of thoracic medical oncology, researchers from the KEYNOTE - 021 study demonstrated for the first time that combining an immune checkpoint inhibitor — in this case, pembrolizumab — with a platinum - doublet chemotherapy regimen might be more effective than chemotherapy alone as first - line treatment for advanced, non-squamous NSCLC.

The combination of the attenuated oncolytic virus talimogene laherparepvec (T - VEC) and the immune checkpoint inhibitor pembrolizumab shows activity and is well tolerated by advanced melanoma patients, according to a new study presented at the Society for Melanoma Research 2015 International Congress, held November 18 — 21 in San Francisco.